Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.

By Michael Gibney • Oct. 12, 2023

A decade later, biotech’s CRISPR revolution is still going strong

Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

5 minutes with — IDEA Pharma’s Mike Rea

The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

By Meagan Parrish • Oct. 11, 2023

Google bets on AI in the life sciences as ‘technology for a purpose’

A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.

By Alexandra Pecci • Oct. 10, 2023

PharmaVoice 100s: Tech wizards

The leaders paving the way to pharma’s future with state-of-the-art digital solutions.

By Karissa Waddick • Oct. 9, 2023

Key upcoming events for pharma execs

Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

By Meagan Parrish • Oct. 6, 2023

3 marketing tips for biotechs emerging from stealth

In a crowded biotech market, here’s how your company can stand out to investors.

By Karissa Waddick • Oct. 6, 2023

FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

By Michael Gibney • Oct. 5, 2023

Drugmakers face uphill battle in Medicare negotiation suits

Judges have found fault with drug manufacturers’ First and Fifth Amendment arguments against the IRA’s drug pricing measures.

By Karissa Waddick • Oct. 4, 2023

5 FDA decisions to watch in the fourth quarter

The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.

By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023

PharmaVoice 100s: Cancer care visionaries

Leaders shaping the future of oncology and cancer care through grit and determination in the face of one of healthcare’s greatest challenges.

By Michael Gibney • Oct. 2, 2023

3 recent FDA adcomm rejections — and why they matter

Decisions that could spell doom for drugs in development and already on the shelves.

By Meagan Parrish • Sept. 29, 2023

The PharmaVoice 100: Trailblazers

Leaders who are going where no biopharma executive has gone before and changing the industry along the way.

By Michael Gibney • Sept. 29, 2023

How pharma marketers can reclaim the drug pricing narrative

As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.

By Karissa Waddick • Sept. 28, 2023

Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk

A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.

By Michael Gibney • Sept. 28, 2023

Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant

Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.

By Karissa Waddick • Sept. 27, 2023

Do humans have a place in pharma’s AI future?

From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.

By Michael Gibney • Sept. 26, 2023

PharmaVoice 100s: Standout execs

Leaders who’ve created unique strategies for thriving amid the heavy headwinds facing the industry.

By Meagan Parrish • Sept. 25, 2023

Elderly exclusion: Clinical trials still fall short enrolling older adults

Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.

By Kelly Bilodeau • Sept. 25, 2023

For Astellas’ CMO, accelerating innovation means working at the edge of your comfort zone

Scientific discovery through new, breakthrough modalities is essential to solve current and future global health challenges – but the path is not easy nor well-defined.

Sept. 25, 2023

As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.

By Michael Gibney • Sept. 21, 2023

What happened to ivermectin?

The saga of the anti-parasitic drug continues.

By Alexandra Pecci • Sept. 20, 2023

PBMs, PhRMA trade blame over drug costs in House hearing

Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second PBM hearing on Tuesday.

By Rebecca Pifer • Sept. 19, 2023

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023

Endangered horseshoe crabs could lead the charge in pharma’s animal-free future

An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.

By Kelly Bilodeau • Sept. 18, 2023